Ken Griffin Scynexis Inc Call Options Transaction History

Citadel Advisors LLC

  • $509 Billion
  • Q1 2024

Call Options

4 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2023

Nov 14, 2023
SELL
$1.93 - $3.64 $35,512 - $66,976
-18,400 Reduced 92.46%
1,500 $3,000
Q2 2023

Aug 14, 2023
SELL
$2.38 - $3.67 $10,710 - $16,515
-4,500 Reduced 18.44%
19,900 $58,000
Q1 2023

May 15, 2023
SELL
$1.15 - $3.0 $11,270 - $29,400
-9,800 Reduced 28.65%
24,400 $73,000
Q4 2022

Feb 14, 2023
BUY
$1.46 - $2.49 $49,932 - $85,158
34,200 New
34,200 $53,000

Others Institutions Holding SCYX

# of Institutions
57
Shares Held
15.4M
Call Options Held
0
Put Options Held
12.9K
View Full List

About SCYNEXIS INC

SCYX Quotes by TradingView
  • Ticker SCYX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 32,651,800
  • Market Cap $63.3M
  • Description
  • SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...
More about SCYX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email